BRCA1 and ovarian carcinoma: After 3 days combinatorial drug therapy, we observed a synergistic effect of the combined drugs in HRDhigh sarcoma cells as well as in BRCA1‐mutated ovarian carcinoma cells, but not in two HRDlow sarcoma cells (compare Fig 5M–O with Fig EV5H and I).